Opportunistic infection and immunologic function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy

Journal of the National Cancer Institute

Volumn 89, Issue 4, 1997, Pages 301-307

  Sparano, Joseph A ^a   Hu, Xiaoping ^a   Wiernik, Peter H ^a   Sarta, Catherine ^a   Reddy, Devarapalli M ^a   Hanau, Larry ^a   Henry, David H ^b  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b GRADUATE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE;

ADULT; AIDS RELATED COMPLEX; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MALE; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; PROPHYLAXIS; RISK FACTOR; STATISTICAL ANALYSIS;

EID: 0031019403     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/89.4.301     Document Type: Article

References (35)

1. Gail MH, Pluda JM, Rabkin CS, Biggar RJ, Goedert JJ, Horm JW, et al. Projections of the incidence of non-Hodgkin's lymphoma related to acquired immunodeficiency syndrome. J Natl Cancer Inst 1991;83: 695-701.
2. Pluda JM, Venzon DJ, Tosato G, Lietzau J, Wyvill K, Nelson DL, et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving anti-retroviral therapy. J Clin Oncol 1993;11:1099-107.
3. Sparano JA. Treatment of AIDS-related lymphomas. Curr Opin Oncol 1995;7:442-9.
4. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker N, Valentine ES. Infusional cyclophosphamide, doxorubicin, and etoposide in human immunodeficiency virus-and human T-cell leukemia virus type I-related non-Hodgkin's lymphoma: a highly active regimen. Blood 1993;81: 2810-5.
5. Sparano JA, Wiernik PH, Strack M, Leaf A, Becker NH, Sarta C, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: a follow-up report of a highly active regimen. Leuk Lymphoma 1994;14:263-71.
6. Sparano JA, Wiernik PH, Leaf A, Henry D, Mason B, Sarta C, et al. Didanosine ameliorates neutropenia in patients with HIV-related non-Hodgkin's lymphoma treated with infusional cyclophosphamide, doxorubicin and etoposide [abstract]. Proc ASCO 1995;36:203.
7. Sparano JA, Wiernik PH, Hu X, Sarta C, Schwartz EL, Soiero R, et al. A pilot trial of infusional cyclophosphamide, doxorubicin and etoposide plus didanosine and filgrastim in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 1996;14:3026-35.
8. Gisselbrecht C, Oksenhendler E, Tirelli U, Lepage E, Gabarre J, Farcet JP, et al. Human immunodeficiency virus-related lymphoma treatment with intensive combination chemotherapy. French-Italian Cooperative Group. Am J Med 1993;95:188-96.
9. Levine AM, Sullivan-Halley J, Pike MC, Rarick MU, Loureiro C, Bernstein-Singer M, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991;68:2466-72.
10. Kaplan LD, Abrams DI, Feigal E, McGrath M, Kahn J, Neville P, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261:719-24.
11. Gill PS, Levine AM, Krailo M, Rarick MU, Loureiro C, Deyton L, et al. AIDS-related malignant lymphoma: results of prospective treatment trials. J Clin Oncol 1987;5:1322-8.
12. Kaplan LD, Kahn JO, Crowe S, Northfelt D, Neville P, Grossberg H, et al. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma: results of a randomized trial. J Clin Oncol 1991;9:929-40.
13. Levine AM, Wernz JC, Kaplan L, Rodman N, Cohen P, Metroka C, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA 1991;266:84-8.
14. Kaplan L, Straus D, Testa M, Levine AM. Randomized trial of standard dose m-BACOD vs reduced dose m-BACOD for systemic HIV-associated lymphoma: ACTG 142 [abstract]. Proc ASCO 1995;14:288.
15. Tirelli U, Errante D, Oksenhendler E, Spina M, Vaccher E, Serraino D, et al. Prospective study with combined low-dose chemotherapy and zidovudine in 37 patients with poor-prognosis AIDS-related non-Hodgkin's lymphoma. French-Italian Cooperative Study Group. Ann Oncol 1992;3:843-7.
16. Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H, et al. Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma. J Clin Oncol 1993;11:1691-702.
17. Hollsberg P, Hafler DA. Seminars in medicine of the Beth Israel Hospital, Boston. Pathogenesis of diseases induced by human lymphotropic virus type I infection. N Engl J Med 1993;328:1173-82.
18. Sande MA, Volberding PA, editors. The medical management of AIDS. Philadelphia: Saunders, 1992.
19. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992;41:1-19.
20. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;24:187-220.
21. Collett D. Modelling survival data in medical research. New York: Chapman & Hall, 1994.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
23. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
24. Crossen JR, Garwood D, Glatstein E, Neuwelt EA. Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. J Clin Oncol 1994;12:627-42.
25. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-6.
26. Moore RD, Hidalgo J, Sugland BW, Chaisson RE. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 1991;324:1412-6.
27. Kahn JO, Lagakos SW, Richman DD, Cross A, Pettinelli C, Liou SH, et al. A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection. The NIAID AIDS Clinical Trials Group. N Engl J Med 1992;327:581-7.
28. + T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995;332:143-9.
29. Levy R, Kaplan HS. Impaired lymphocyte function in untreated Hodgkin's disease. N Engl J Med 1974;290:181-6.
30. Anderson TC, Jones SE, Soehnlen BJ, Moon TE, Griffith K, Stanley P. Immunocompetence and malignant lymphoma: immunologic status before therapy. Cancer 1981;48:2702-9.
31. + lymphocytes are an incomplete surrogate marker for clinical progression in persons with asymptomatic HIV infection taking zidovudine. Ann Intern Med 1993;118: 674-80.
32. + lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996;334:426-31.
33. Kitahata MM, Koepsell TD, Deyo RA, Maxwell CL, Dodge WT, Wagner EH. Physicians' experience with the acquired immunodeficiency syndrome as a factor in patients' survival. N Engl J Med 1996;334:701-6.
34. Ioannidis JP, Cappelleri JC, Lau J, Skolnik PR, Melville B, Chalmers TC, et al. Early or deferred zidovudine therapy in HIV-infected patients without an AIDS-defining illness. Ann Intern Med 1995;122:856-66.
35. Ho DD. Time to hit HIV, early and hard [editorial]. N Engl J Med 1995; 333:450-1.